- Shares of Twist Bioscience Corp (NASDAQ:TWST) fell after the firm issued fiscal second-quarter revenue guidance that fell below the consensus Wall Street estimate.
- For Q1 FY23, Twist posted a 29% increase in sales to $54.2 million, almost in line with the consensus of $54.1 million.
- The company shipped approximately 134,000 genes during the quarter to 2,060 customers, compared to about 1,800 customers during the year-ago quarter.
- For Q1, the company reported an EPS loss of $(0.74), down from $(0.91) a year ago compared to the consensus of $(1.13).
- Guidance: Twist Bioscience expects fiscal Q2 revenues of $56.5 million, below the consensus of $61.9 million, with $24 million in synbio revenues, $25 million in next-generation sequencing revenues, and biopharma revenues of $7.5 million.
- It anticipates full-year fiscal 2023 revenue of $261 million to $269 million, which remains unchanged.
- Price Action: TWST shares are down 16.6% at $25.77 on the last check Friday.
Evogene Q3 EPS $(0.16) Beats $(0.20) Estimate, Sales $466.00K Beat $100.00K Estimate. Cash, Cash Equivalents And Marketable Securities Of $$38M
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the same
